We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biglycan in the Tumor Microenvironment May Act As Metastasis Trigger

By LabMedica International staff writers
Posted on 25 Jul 2016
Print article
Image: A strong biglycan signal (red) was detected in the tumor blood vessel area of a metastatic case (right) but was barely detected in the tumor tissues of a non-metastatic case (left) (Photo courtesy of Maishi N. et al., Scientific Reports).
Image: A strong biglycan signal (red) was detected in the tumor blood vessel area of a metastatic case (right) but was barely detected in the tumor tissues of a non-metastatic case (left) (Photo courtesy of Maishi N. et al., Scientific Reports).
A small proteoglycan secreted from endothelial cells within the tumor microenvironment has been linked to the likelihood of the primary tumor metastasizing and freeing cells to travel to other parts of the body.

Investigators at Hokkaido University (Japan) had demonstrated earlier that features of tumor endothelial cells (TECs) were different depending on tumor malignancy, suggesting that TECs communicated with surrounding tumor cells. However, the mechanism of this communication, especially its relation to metastasis, had not been elucidated.

In the current study, which was published in the June 13, 2016, online edition of the journal Scientific Reports, the investigators described the role of biglycan on tumor metastasis. Biglycan is a small leucine-rich repeat proteoglycan (SLRP) which is found in a variety of extracellular matrix tissues, including bone, cartilage, and tendon. In humans, biglycan is encoded by the BGN gene, which is located on the X chromosome. Biglycan consists of a protein core containing leucine-rich repeat regions and two glycosaminoglycan (GAG) chains consisting of either chondroitin sulfate (CS) or dermatan sulfate (DS), with DS being more abundant in most connective tissues.

The investigators reported that high biglycan expression was associated with poor prognosis in patients with breast, lung, and colorectal cancer. High levels of biglycan were found in the blood of patients with metastatic cancer, while the molecule was barely detectable in the non-metastatic disease.

The investigators also worked with mouse models of low-metastatic (LM) and high-metastatic (HM) melanoma tumors. They found that co-implantation of TECs isolated from highly metastatic tumors accelerated lung metastases of low metastatic tumors. Biglycan synthesis was upregulated by DNA demethylation in TECs, which secreted the substance, activating tumor cell migration via nuclear factor-kappaB.

The investigators said, "The present observations, together with unravelling certain remaining issues, may contribute to establishing accurate diagnostics or potent anti-metastatic strategies that target the communications between tumor cells and endothelial cells."

Related Links:
Hokkaido University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.